Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.1 SEK | +3.12% | +5.00% | +62.91% |
Sales 2024 * | 52M 4.94M | Sales 2025 * | 393M 37.32M | Capitalization | 2.58B 245M |
---|---|---|---|---|---|
Net income 2024 * | -236M -22.4M | Net income 2025 * | -173M -16.42M | EV / Sales 2024 * | 42.1 x |
Net cash position 2024 * | 391M 37.14M | Net cash position 2025 * | 210M 19.95M | EV / Sales 2025 * | 6.03 x |
P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-9.82
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.03% |
Latest transcript on Vicore Pharma Holding AB
1 day | +3.13% | ||
1 week | +5.00% | ||
Current month | +5.00% | ||
1 month | +15.21% | ||
3 months | +50.20% | ||
6 months | +59.75% | ||
Current year | +62.91% |
Managers | Title | Age | Since |
---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 23-09-08 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 16-12-31 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 17-12-31 | |
Chairman | 66 | 17-12-31 | |
Michael Buschle
BRD | Director/Board Member | 64 | 22-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 23.1 | +3.13% | 318,378 |
24-06-05 | 22.4 | -3.86% | 277,729 |
24-06-04 | 23.3 | +1.30% | 535,623 |
24-06-03 | 23 | +4.55% | 749,049 |
24-05-31 | 22 | +15.18% | 1,414,509 |
Delayed Quote Nasdaq Stockholm, June 07, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.91% | 245M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- VICO Stock